These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23439751)

  • 1. Cancer of unknown primary origin: using ancillary techniques with caution.
    Bhargava R; Dabbs DJ
    J Clin Oncol; 2013 Apr; 31(11):1478-9. PubMed ID: 23439751
    [No Abstract]   [Full Text] [Related]  

  • 2. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI.
    Gross-Goupil M; Massard C; Lesimple T; Merrouche Y; Blot E; Loriot Y; Mathieu MC; Fizazi K
    Onkologie; 2012; 35(1-2):54-5. PubMed ID: 22310348
    [No Abstract]   [Full Text] [Related]  

  • 3. [Insufficient studies of diagnostic cancer tests. Neither systematic review nor original studies come up to expectations].
    Holmberg L
    Lakartidningen; 2007 Apr 25-May 1; 104(17):1308-9. PubMed ID: 17547275
    [No Abstract]   [Full Text] [Related]  

  • 4. The STARD initiative: a possible link to diagnostic accuracy and reduction in medical error.
    McQueen MJ
    Ann Clin Biochem; 2003 Jul; 40(Pt 4):307-8. PubMed ID: 12880531
    [No Abstract]   [Full Text] [Related]  

  • 5. New methods in the assessment of diagnostic procedures.
    Kleijnen J
    Z Arztl Fortbild Qualitatssich; 2006; 100(7):519-25. PubMed ID: 17137065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostics: new methodological initiatives].
    Magid E; Jørgensen PE; Jørgensen LG; Madsen JS; Larsen TB; Hilden J
    Ugeskr Laeger; 2004 Apr; 166(18):1664-6. PubMed ID: 15174402
    [No Abstract]   [Full Text] [Related]  

  • 7. [Using characteristic numbers to estimate the usefulness of laboratory tests for diagnosis].
    Uhari M
    Duodecim; 2004; 120(8):935-41. PubMed ID: 15185506
    [No Abstract]   [Full Text] [Related]  

  • 8. Readers' responses to "Cancer of unknown primary site: advances in diagnostics".
    Emmons R; Morris GJ
    Semin Oncol; 2010 Dec; 37(6):555. PubMed ID: 21167373
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
    Horlings HM; van Laar RK; Kerst JM; Helgason HH; Wesseling J; van der Hoeven JJ; Warmoes MO; Floore A; Witteveen A; Lahti-Domenici J; Glas AM; Van't Veer LJ; de Jong D
    J Clin Oncol; 2008 Sep; 26(27):4435-41. PubMed ID: 18802156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer of unknown primary site: evolving understanding and management of patients.
    Greco FA
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):518-24. PubMed ID: 23073050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
    Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
    Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic work-up and outcome of cervical metastases from an unknown primary.
    Guntinas-Lichius O; Peter Klussmann J; Dinh S; Dinh M; Schmidt M; Semrau R; Mueller RP
    Acta Otolaryngol; 2006 May; 126(5):536-44. PubMed ID: 16698706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Danish clinical guidelines (Klaringsrapporter, 1996-2001: Insufficient evidence presented for the diagnostic accuracy of recommended clinical-biochemical tests].
    Jørgensen PE; Madsen JS; Jørgensen LG; Larsen TB; Hilden J; Magid E
    Ugeskr Laeger; 2004 Apr; 166(18):1667-70. PubMed ID: 15174403
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of diagnostic methods].
    Doyon F; Hill C
    J Radiol; 2001 Feb; 82(2):117-25. PubMed ID: 11428206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary: cutting edge or already obsolete?
    Dolled-Filhart MP; Rimm DL
    Cancer Cytopathol; 2013 Mar; 121(3):129-35. PubMed ID: 22927160
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular profiling of a tumor of unknown origin.
    Ismael G; de Azambuja E; Awada A
    N Engl J Med; 2006 Sep; 355(10):1071-2. PubMed ID: 16957161
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical use of diagnostic tests (Part 1): Analysis of the properties of a diagnostic test].
    Cerda L J; Cifuentes A L
    Rev Chilena Infectol; 2010 Jun; 27(3):205-8. PubMed ID: 20737121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression analysis and immunohistochemistry in evaluation of cancer of unknown primary: time for a patient-centered approach.
    Handorf CR
    J Natl Compr Canc Netw; 2011 Dec; 9(12):1415-20. PubMed ID: 22157559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.